Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 2

Status

Active not recruiting 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Hepatitis, Chronic 1Hepatitis C 1Glioblastoma 1Carcinoma, Hepatocellular 1BRCA1/2 Mutation 1

Interventions

pembrolizumab 257Cyclophosphamide 241Specimen Handling 198fludarabine 173Magnetic Resonance Spectroscopy 173Biopsy 147Nivolumab 119Carboplatin 97Radiotherapy 92Paclitaxel 85venetoclax 82Cisplatin 80Gemcitabine 79fludarabine phosphate 78Injections 68Ipilimumab 64Dexamethasone 61atezolizumab 59Bevacizumab 58Cetuximab 57Radiation 55Fluorouracil 55Azacitidine 55durvalumab 54Radiosurgery 52Temozolomide 47Rituximab 44Oxaliplatin 44Irinotecan 43Docetaxel 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × rocakinogene sifuplasmid × 1 year × Clear all
NCT04015700 2026-05-07

Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Washington University School of Medicine

Phase 1 Active not recruiting
9 enrolled 14 charts
CNS

Glioblastoma

NCT02772003 2026-04-13

DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

National Cancer Institute (NCI)

Phase 1 Active not recruiting
33 enrolled
Gastrointestinal

Hepatitis, Chronic, Hepatitis C, Carcinoma, Hepatocellular

NCT04367675 2026-02-23

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

Abramson Cancer Center at Penn Medicine

Phase 1 Active not recruiting
44 enrolled

BRCA1/2 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡